Teza Capital Management LLC Takes $900,000 Position in Agilent Technologies, Inc. (NYSE:A)

Teza Capital Management LLC acquired a new stake in Agilent Technologies, Inc. (NYSE:A - Free Report) in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm acquired 6,699 shares of the medical research company's stock, valued at approximately $900,000.

A number of other hedge funds also recently made changes to their positions in the business. True Wealth Design LLC lifted its position in Agilent Technologies by 3,450.0% during the fourth quarter. True Wealth Design LLC now owns 355 shares of the medical research company's stock worth $48,000 after acquiring an additional 345 shares during the last quarter. Strategic Global Advisors LLC lifted its position in Agilent Technologies by 4.2% during the fourth quarter. Strategic Global Advisors LLC now owns 24,591 shares of the medical research company's stock worth $3,304,000 after acquiring an additional 999 shares during the last quarter. Toronto Dominion Bank lifted its position in Agilent Technologies by 5.8% during the fourth quarter. Toronto Dominion Bank now owns 153,898 shares of the medical research company's stock worth $20,674,000 after acquiring an additional 8,420 shares during the last quarter. Royal Bank of Canada lifted its position in Agilent Technologies by 4.9% during the fourth quarter. Royal Bank of Canada now owns 834,041 shares of the medical research company's stock worth $112,045,000 after acquiring an additional 39,321 shares during the last quarter. Finally, Rafferty Asset Management LLC lifted its position in Agilent Technologies by 10.1% during the fourth quarter. Rafferty Asset Management LLC now owns 32,580 shares of the medical research company's stock worth $4,377,000 after acquiring an additional 2,987 shares during the last quarter.

Agilent Technologies Stock Up 1.2%

Shares of A opened at $113.76 on Monday. Agilent Technologies, Inc. has a one year low of $96.43 and a one year high of $154.95. The company has a market cap of $32.43 billion, a P/E ratio of 26.15, a P/E/G ratio of 3.21 and a beta of 1.27. The company has a debt-to-equity ratio of 0.56, a current ratio of 2.20 and a quick ratio of 1.66. The firm has a 50 day simple moving average of $110.44 and a two-hundred day simple moving average of $128.16.

Agilent Technologies (NYSE:A - Get Free Report) last posted its earnings results on Wednesday, February 26th. The medical research company reported $1.31 earnings per share for the quarter, topping analysts' consensus estimates of $1.27 by $0.04. The firm had revenue of $1.68 billion for the quarter, compared to analysts' expectations of $1.67 billion. Agilent Technologies had a net margin of 19.27% and a return on equity of 25.56%. Research analysts forecast that Agilent Technologies, Inc. will post 5.54 EPS for the current fiscal year.

Agilent Technologies Announces Dividend

The business also recently announced a quarterly dividend, which was paid on Wednesday, April 23rd. Shareholders of record on Tuesday, April 1st were paid a dividend of $0.248 per share. The ex-dividend date of this dividend was Tuesday, April 1st. This represents a $0.99 dividend on an annualized basis and a dividend yield of 0.87%. Agilent Technologies's payout ratio is presently 22.76%.

Insiders Place Their Bets

In related news, Director Daniel K. Podolsky sold 1,819 shares of the business's stock in a transaction on Monday, March 31st. The shares were sold at an average price of $116.46, for a total value of $211,840.74. Following the sale, the director now owns 35,737 shares of the company's stock, valued at $4,161,931.02. The trade was a 4.84% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, VP Rodney Gonsalves sold 1,908 shares of the business's stock in a transaction on Monday, March 17th. The stock was sold at an average price of $121.98, for a total transaction of $232,737.84. Following the completion of the sale, the vice president now directly owns 21,786 shares in the company, valued at approximately $2,657,456.28. This represents a 8.05% decrease in their position. The disclosure for this sale can be found here.

Analyst Ratings Changes

Several equities research analysts have issued reports on the stock. Wells Fargo & Company cut their price objective on shares of Agilent Technologies from $155.00 to $135.00 and set an "overweight" rating for the company in a research report on Thursday, April 17th. Jefferies Financial Group dropped their price target on shares of Agilent Technologies from $135.00 to $116.00 and set a "hold" rating for the company in a research report on Monday, April 21st. Robert W. Baird dropped their price target on shares of Agilent Technologies from $161.00 to $159.00 and set an "outperform" rating for the company in a research report on Thursday, February 27th. Barclays dropped their price target on shares of Agilent Technologies from $138.00 to $115.00 and set an "equal weight" rating for the company in a research report on Thursday, April 10th. Finally, TD Cowen lifted their price target on shares of Agilent Technologies to $135.00 and gave the company a "buy" rating in a research report on Thursday, April 10th. Seven equities research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the stock. According to data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and an average target price of $143.00.

About Agilent Technologies

Agilent Technologies, Inc provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The company operates in three segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; cell imaging systems; microplate reader; laboratory software; information management and analytics; laboratory automation and robotic systems; dissolution testing; and vacuum pumps, and measurement technologies.

Want to see what other hedge funds are holding A? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Agilent Technologies, Inc. (NYSE:A - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.